| C09DA01 |
Losartan, Hydrochlorithiazide |
TORES |
Film coated tablet |
50 mg/12,5 mg |
mg |
30 |
Stada Arzneimittel AG, Германия |
1 |
tabl |
- |
6 |
0.19714 |
5.91 |
50% |
2.95 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 70/ 19.04.2010; КЦРР-652/19.05.2012 г.; КЦРР-1184/13.08.2012 г.; КЦРР-2179/06.02.2013 г; НСР-3139/26.03.2014; НСР-6231/21.05.2015 |
02.09.2019 |
08.09.2012 |
16.11.2013 |
Активен |
2628 |
| C09DA01 |
Losartan, Hydrochlorithiazide |
Zatan H |
Film coated tablet |
50 mg/12,5 mg |
mg |
30 |
Софарма АД, България |
1 |
tabl |
- |
6.02 |
0.18467 |
5.54 |
50% |
2.77 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-2911/05.03.2014; НСР-9847/21.07.2016 |
02.09.2016 |
|
|
Заличен |
2601 |
| C09DA01 |
Losartan, Hydrochlorithiazide |
Zatan H |
Film coated tablet |
50 mg/12,5 mg |
mg |
30 |
Софарма АД, България |
1 |
tabl |
- |
6.02 |
0.20108 |
6.03 |
50% |
3.02 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1578/05.11.2012 г; НСР-2046/11.12.2013; HCP-5715/26.02.2015. |
16.03.2015 |
|
|
Заличен |
2601 |
| C09DA02 |
Eprosartan/ Hydrochlorothiazide |
C09DA02 Eprosartan/ Hydrochlorothiazide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C09DA02 |
Eprosartan, Hydrochlorothiazide |
Teveten Plus |
Film coated tablet |
600 mg/12,5 mg |
mg |
14 |
Mylan Healthcare GmbH, Германия |
1 |
tabl |
- |
22.01 |
1.03375 |
14.47 |
50% |
7.23 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1427/25.09.2012 г; НСР-3252/14.04.2014.; НСР-7875/25.01.2016.; НСР-18160/07.03.2019 |
02.04.2019 |
08.09.2012 |
|
Заличен |
460 |
| C09DA03 |
Valsartan/hydrochlorothiazide |
C09DA03 Valsartan/hydrochlorothiazide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Diovan |
Film coated tablet |
160 mg/12.5 mg |
|
14 |
Беста Мед ЕООД, България |
1 |
tabl |
- |
14.4 |
0.32767 |
4.59 |
50% |
2.29 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-19485/07.08.2019- Паралелен внос |
02.09.2019 |
|
|
Активен |
16656 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
CO-DIOVAN |
Film coated tablet |
160 mg/25 mg |
mg |
14 |
Novartis Pharma GmbH, Германия |
1 |
tabl |
- |
11.35 |
0.23964 |
3.36 |
50% |
1.68 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-2212/06.02.2013 г; НСР-1733/21.11.2013; НСР-4326/05.08.2014.; НСР-7196/09.10.2015.; НСР-14549/30.11.2017; НСР-17884/07.02.2019 |
02.03.2019 |
08.09.2012 |
|
Активен |
3089 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
CO-DIOVAN |
Film coated tablet |
160 mg/ 12.5 mg |
mg |
14 |
Novartis Pharma GmbH, Германия |
1 |
tabl |
- |
14.4 |
0.32767 |
4.59 |
50% |
2.29 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-2212/06.02.2013 г; НСР-1733/21.11.2013; НСР-4325/05.08.2014.; НСР-7195/09.10.2015. |
02.06.2017 |
08.09.2012 |
|
Активен |
3088 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Sartoval |
Film coated tablet |
160 mg/25 mg |
mg |
30 |
Алвоген Фарма Трейдинг Юръп ЕООД, България |
1 |
tabl |
- |
9.83 |
0.23964 |
7.19 |
50% |
3.59 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-6016/09.04.2015.; КП-68/12.09.2017 и НСР-13052/23.06.2017; НСР-19610/21.08.2019; НСР-20959/05.03.2020; НСР-21100/30.03.2020 Предварително изпълнение |
02.04.2020 |
|
|
Активен |
3818 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Sartoval |
Film coated tablet |
160 mg/ 25 mg |
mg |
28 |
Тева Фармасютикълс България ЕООД, България |
1 |
tabl |
- |
6 |
0.21429 |
6 |
50% |
3 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 124/ 13.12.2010; НСР-2303/13.01.2014; КП-323/17.06.2015 и НСР-6150/29.04.2015.; НСР-6802/23.07.2015 |
16.08.2015 |
08.09.2012 |
|
Заличен |
2466 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valsacor |
Film coated tablet |
320 mg/ 25 mg |
mg |
30 |
KRKA, d.d., Словения |
1 |
tabl |
- |
18.83 |
0.61321 |
18.4 |
50% |
9.2 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-7506/19.11.2015. |
02.10.2017 |
|
|
Активен |
4142 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valsacor |
Film coated tablet |
320 mg/ 12.5 mg |
mg |
30 |
KRKA, d.d., Словения |
1 |
tabl |
- |
18.83 |
0.58575 |
17.57 |
50% |
8.79 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-7506/19.11.2015. |
02.04.2016 |
|
|
Активен |
4141 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valsacor |
Film coated tablet |
160 mg/25 mg |
mg |
28 |
KRKA, d.d., Словения |
1 |
tabl |
- |
11.12 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 43/07.01.2010; № 238/04.11.2011; НСР-1334/07.10.2013; НСР-3688/06.06.2014.; НСР-6934/12.08.2015; НСР-10805/03.11.2016 |
02.12.2016 |
08.09.2012 |
|
Активен |
2895 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valsacor |
Film coated tablet |
160 mg/12,5 mg |
mg |
28 |
KRKA, d.d., Словения |
1 |
tabl |
- |
11.12 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 43/07.01.2010; № 238/04.11.2011; НСР-1333/07.10.2013; НСР-3688/06.06.2014; НСР-6934/12.08.2015; НСР-10806/03.11.2016 |
02.06.2017 |
08.09.2012 |
|
Активен |
2896 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valsacor |
Film coated tablet |
80 mg/ 12,5 mg |
mg |
28 |
KRKA, d.d., Словения |
1 |
tabl |
- |
11.92 |
0.25607 |
7.17 |
50% |
3.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 43/07.01.2010; НСР-2047/11.12.2013 |
02.01.2014 |
08.09.2012 |
|
Заличен |
815 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valstor |
Film coated tablet |
160 mg/12,5 mg |
mg |
30 |
Чайкафарма Висококачествените лекарства АД, България |
1 |
tabl |
- |
21.8 |
0.32767 |
9.83 |
50% |
4.91 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1708/27.11.2012 г.; НСР-20186/22.11.2019 |
02.01.2020 |
|
|
Заличен |
1107 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Co-Valstor |
Film coated tablet |
160 mg/25 mg |
mg |
30 |
Чайкафарма Висококачествените лекарства АД, България |
1 |
tabl |
- |
21.8 |
0.23964 |
7.19 |
50% |
3.59 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1497/15.10.2012 г.; НСР-12087/21.03.2017 |
02.05.2017 |
|
|
Заличен |
1108 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Sarteg HCT |
Film coated tablet |
80 mg/ 12,5 mg |
mg |
28 |
EGIS Pharmaceuticals PLC, Унгария |
1 |
tabl |
- |
11.23 |
0.17839 |
4.99 |
50% |
2.49 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№25/03.08.2009; НСР-2825/21.02.2014 и КП-5/15.01.2015; НСР-6274/22.05.2015 (допуска предварително изпълнение) |
02.06.2015 |
08.09.2012 |
|
Заличен |
3501 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Sarteg HCT |
Film coated tablet |
160 mg/ 12.5 mg |
mg |
28 |
EGIS Pharmaceuticals PLC, Унгария |
1 |
tabl |
- |
10.82 |
0.27303 |
7.64 |
50% |
3.82 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№25/03.08.2009; НСР-2823/21.02.2014 и КП-3/15.01.2015; НСР-6271/22.05.2015 (допуска предварително изпълнение) |
02.06.2015 |
08.09.2012 |
|
Заличен |
3499 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Sarteg HCT |
Film coated tablet |
160 mg/ 25 mg |
mg |
28 |
EGIS Pharmaceuticals PLC, Унгария |
1 |
tabl |
- |
10.22 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№25/03.08.2009; НСР-843/07.08.2014и КП-16/05.03.2014 ; НСР-2824/21.02.2014 и КП-2/15.01.2015; НСР-6273/22.05.2015 (допуска предварително изпълнение) |
02.06.2015 |
08.09.2012 |
|
Заличен |
3498 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
SARTEG HCT |
Film coated tablet |
160 mg/25 mg |
mg |
30 |
EGIS Pharmaceuticals PLC, Унгария |
1 |
tabl |
- |
9.83 |
0.23964 |
7.19 |
50% |
3.59 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-6076/23.04.2015.; НСР-10093/18.08.2016; КП-10/15.02.2018 и НСР-14661/20.12.2017; НСР-18651/03.05.2019 |
02.06.2019 |
|
|
Заличен |
3843 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
SARTEG HCT |
Film coated tablet |
80 mg/12,5 mg |
mg |
30 |
EGIS Pharmaceuticals PLC, Унгария |
1 |
tabl |
- |
9.83 |
0.20925 |
6.28 |
50% |
3.14 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-6074/23.04.2015.; НСР-10091/18.08.2016; КП-11/15.02.2018 и НСР-14663/20.12.2017; НСР-18652/03.05.2019 |
02.06.2019 |
|
|
Заличен |
3841 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
SARTEG HCT |
Film coated tablet |
160 mg/12,5 mg |
mg |
30 |
EGIS Pharmaceuticals PLC, Унгария |
1 |
tabl |
- |
9.83 |
0.32767 |
9.83 |
50% |
4.91 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-6075/23.04.2015.; НСР-10092/18.08.2016; КП-12/15.02.2018 и НСР-14662/20.12.2017; НСР-18654/07.05.2019 |
02.06.2019 |
|
|
Заличен |
3842 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Suvartar H |
Film coated tablet |
160 mg/12,5 mg |
mg |
28 |
Sandoz d.d., Словения |
1 |
tabl |
- |
11.12 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1704/27.11.2012 г.; НСР-5548/29.01.2015; НСР-9203/05.05.2016 |
02.06.2017 |
|
|
Активен |
3560 |